Mesoblast (MESO) Competitors $16.28 +0.03 (+0.15%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, and CRSPShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Grifols Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics Mesoblast (NASDAQ:MESO) and Grifols (NASDAQ:GRFS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Does the media prefer MESO or GRFS? In the previous week, Mesoblast had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Mesoblast and 2 mentions for Grifols. Grifols' average media sentiment score of 1.00 beat Mesoblast's score of 0.84 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in MESO or GRFS? 1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, MESO or GRFS? Grifols has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$17.20M121.19-$102.14MN/AN/AGrifols$7.81B0.86$169.80M$1.178.37 Which has more volatility & risk, MESO or GRFS? Mesoblast has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Is MESO or GRFS more profitable? Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Grifols N/A N/A N/A Do analysts recommend MESO or GRFS? Mesoblast presently has a consensus price target of $24.00, indicating a potential upside of 47.37%. Grifols has a consensus price target of $10.30, indicating a potential upside of 5.21%. Given Mesoblast's stronger consensus rating and higher possible upside, equities research analysts clearly believe Mesoblast is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryMesoblast beats Grifols on 8 of the 11 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.08B$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E RatioN/A20.6875.7026.05Price / Sales121.19397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book3.499.6212.876.29Net Income-$102.14M-$52.73M$3.29B$270.94M7 Day Performance3.40%0.59%-0.33%-0.30%1 Month Performance3.66%6.27%3.77%6.20%1 Year Performance133.31%18.55%68.18%28.32% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast2.1529 of 5 stars$16.29+0.2%$24.00+47.4%+123.7%$2.08B$17.20M0.0080GRFSGrifols3.839 of 5 stars$9.63-2.5%$10.30+7.0%+13.3%$6.79B$7.81B8.2323,822News CoverageRYTMRhythm Pharmaceuticals3.1879 of 5 stars$96.03-0.2%$101.57+5.8%+89.1%$6.39B$130.13M-31.90140Trending NewsAnalyst ForecastABVXAbivax3.0313 of 5 stars$85.87+2.2%$99.43+15.8%+629.9%$6.35BN/A0.0061Analyst ForecastCYTKCytokinetics4.23 of 5 stars$49.44-3.3%$75.38+52.5%-8.3%$6.12B$18.47M-9.69250Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.2088 of 5 stars$33.88+2.3%$74.22+119.1%-27.4%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.8237 of 5 stars$116.78-1.4%$177.86+52.3%+30.1%$5.91B$385.69M-23.03380Insider TradeNUVLNuvalent3.1991 of 5 stars$79.37-1.4%$120.91+52.3%-21.5%$5.80BN/A-16.2040Positive NewsRNAAvidity Biosciences2.0899 of 5 stars$40.22-10.1%$68.94+71.4%-1.8%$5.76B$10.90M-11.30190Analyst ForecastMRUSMerus2.7407 of 5 stars$68.09-2.1%$88.75+30.3%+43.2%$5.26B$36.13M-12.3837Positive NewsCRSPCRISPR Therapeutics3.1647 of 5 stars$57.84+2.8%$71.60+23.8%+30.5%$5.12B$37.31M-10.65460Analyst Forecast Related Companies and Tools Related Companies GRFS Competitors RYTM Competitors ABVX Competitors CYTK Competitors LEGN Competitors AXSM Competitors NUVL Competitors RNA Competitors MRUS Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
